Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, shared a post on LinkedIn:
“Today Bristol Myers Squibb announced that the Phase 3 SUCCESSOR-2 study in relapsed or refractory multiple myeloma met its primary endpoint. This marks the second positive Phase 3 study from our CELMoD portfolio.
These data build upon our longstanding leadership in multiple myeloma and reinforce the promise of our CELMoD platform, which is designed to deliver effective and accessible treatment options for patients with difficult‑to‑treat blood cancers and beyond.
I am deeply grateful to the patients and families who participated in this study, the investigators and site teams who conducted the trial, and the many colleagues whose dedication and collaboration made this progress possible.”
Other articles featuring Cristian Massacesi on OncoDaily.